Genvoya (elvitegravir;cobicistat;emtricitabine;tenofovir alafenamide)
- Region
- 🇪🇺 EU
- Active substance
- elvitegravir;cobicistat;emtricitabine;tenofovir alafenamide
- Company
- Gilead Sciences Ireland UC
- Status
- Authorised
- Therapeutic area
- HIV Infections
- CHMP opinion
- Thu 24 Sep 2015
- EU approval
- Thu 19 Nov 2015
- Application
- EMEA/H/C/004042
- ATC
- J05AR
- Official record
- www.ema.europa.eu
Indication
Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.
Regulatory milestones
No milestones recorded in the last year.
Follow Genvoya
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.